Ixazomib in POEMS syndrome: 'Ixa'ctly what we need?

Published in: British journal of haematology (2024)

The role of the proteasome inhibitor ixazomib in the treatment of POEMS syndrome continues to evolve. He and colleagues present the results of a study investigating ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed POEMS patients. The triplet showed excellent efficacy and tolerability, and constitutes an effective treatment option for patients with POEMS. Commentary on: He et al. An open-label, prospective trial to evaluate the efficacy and safety of ixazomib in combination with cyclophosphamide and dexamethasone in patients with newly-diagnosed POEMS syndrome. Br J Haematol 2024;205:478-482.

Keyphrases

newly diagnosed
high dose
low dose
end stage renal disease
clinical trial
ejection fraction
chronic kidney disease
study protocol
peritoneal dialysis
randomized controlled trial
phase ii
patient reported